For psoriasis, a cream containing
fixed dose combination of calcipotriol and betamethasone dipropionate is better
than the currently available topical suspension/gel.
For the topical management of plaque psoriasis, the new fixed dose combination of betamethasone dipropionate (BDP) and calcipotriol (CAL) cream based on PAD Technology (CAL/BDP PAD-cream) provides superior efficacy, enhanced patient quality of life, and equivalent favorable safety when compared to the currently marketed CAL/BDP topical suspension/gel [CAL/BDP TS], says a study published in The Journal of the European Academy of Dermatology and Venereology.
In this study, the data from two phase III, randomized, multicenter, investigator-blind, active, and vehicle-controlled trials that recruited psoriasis people were pooled and evaluated. Investigational products included CAL/BDP PAD-cream designed for higher skin penetration and better patient preference, an active control (CAL/BDP TS), and a cream vehicle, that were applied once daily for eight weeks.
Both CAL/BDP PAD-cream and CAL/BDP TS were compared in terms of quality of life, safety, and efficacy. For mitigating psoriasis, the new CAL/BDP PAD-cream formulation showed superior efficacy and safety following eight weeks of therapy. Compared to the CAL/BDP TS group, the CAL/BDP PAD-cream group exhibited higher values for physician global assessment (PGA) therapeutic success, mean percent decline in modified Psoriasis Area and Severity Index (mPASI), and Dermatology Life Quality Index (DLQI) 0/1, as shown in Table 1:
There were no CAL/BDP
PAD-cream-elicited adverse drug reactions with a frequency of >1%. Thus,
CAL/BDP PAD-cream is better than CAL/BDP TS for the management of plaque
psoriasis.
The Journal of the European Academy of Dermatology and Venereology
A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis
A Pinter et al.
Comments (0)